Companion Animal Postoperative Pain Management Therapeutics Market To Reach $329.47 Million By 2030

Companion Animal Postoperative Pain Management Therapeutics Market Growth & Trends

The global companion animal postoperative pain management therapeutics market size is expected to reach USD 329.47 million by 2030, registering to grow at a CAGR of 9.45% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing number of surgeries in companion animals is driving the demand for postoperative pain management drugs.

Increasing companion healthcare expenditure and concerns among pet owners is further propelling the market growth. According to The American Pet Products Association report 2024, the overall spending in U.S. pet industry has increased during forecast period. Significant rise in animal insurance policies helps pet owners take proper care of their pets. For instance, in 2024, maximum pet insurance claims were reported for chronic diseases such as arthritis in pets in U.S. According to a report by the Department of Clinical Veterinary Science and the Pet Food Institute.

 Request a free sample copy or view report summary: Companion Animal Postoperative Pain Management Therapeutics Market Report

Companion Animal Postoperative Pain Management Therapeutics Market Report Highlights

• Dogs accounted for 46.8% of revenue share in 2024. This can be attributed to the high number of surgical procedures performed on dogs, particularly orthopedic surgeries and dental procedures.

• NSAIDs held the largest market share of 42.4% in 2024. This dominance is due to the widespread use of NSAIDs in managing pain and inflammation in pets, particularly after surgeries. NSAIDs are favored for their effectiveness in reducing pain, swelling, and fever, making them a go-to choice for veterinarians.

• The oral segment held 86.6% of the market share in 2024 attributed to the ease of administration and the preference for oral medications among pet owners. Oral pain management drugs, such as NSAIDs and opioids, are commonly prescribed for postoperative care in companion animals.

• The veterinary hospitals and clinics segment dominated the market in 2024 due to the high volume of surgical procedures performed in these settings, which necessitates effective pain management solutions.

Companion Animal Postoperative Pain Management Therapeutics Market Segmentation

Grand View Research has segmented the global companion animal postoperative pain management therapeutics market based on animal, product, route of administration, end use, and region:

Companion Animal Postoperative Pain Management Therapeutics Animal Outlook (Revenue, USD Million, 2018 - 2030)

• Dogs

• Cats

• Horses

• Other Companion Animals

Companion Animal Postoperative Pain Management Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)

• NSAIDs

• Anesthetics

• Opioids

• Others

Companion Animal Postoperative Pain Management Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

Companion Animal Postoperative Pain Management Therapeutics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Retail

• E-Commerce

• Veterinary Hospitals & Clinics

Companion Animal Postoperative Pain Management Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • KSA

  • UAE

  • South Africa

  • Kuwait

List of Key Players in Companion Animal Postoperative Pain Management Therapeutics Market 

• Zoetis

• Merck Animal Health

• Elanco

• Norbrook

• Ceva Sante Animale

• Dechra Pharmaceuticals Plc (EQT)

• Boehringer Ingelheim International GmbH

• Chanelle Pharma (Exponent)

• Bimeda Corporate

• Vetoquinol